A Phase II Study From the POLA National Network of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas
Latest Information Update: 06 Jul 2022
At a glance
- Drugs Nivolumab (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Acronyms REVOLUMAB
Most Recent Events
- 07 Jun 2022 Primary endpoint (24 weeks progression-free survival (PFS24w) rate, documented by RANO criteria) has not been met, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2022 Results assessing efficacy of the anti-PD1 nivolumab in recurrent IDH-mutant high-grade gliomas, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 13 Dec 2021 Status changed from active, no longer recruiting to completed.